373 related articles for article (PubMed ID: 21920963)
1. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
Lønborg J; Vejlstrup N; Kelbæk H; Bøtker HE; Kim WY; Mathiasen AB; Jørgensen E; Helqvist S; Saunamäki K; Clemmensen P; Holmvang L; Thuesen L; Krusell LR; Jensen JS; Køber L; Treiman M; Holst JJ; Engstrøm T
Eur Heart J; 2012 Jun; 33(12):1491-9. PubMed ID: 21920963
[TBL] [Abstract][Full Text] [Related]
2. Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study.
Woo JS; Kim W; Ha SJ; Kim JB; Kim SJ; Kim WS; Seon HJ; Kim KS
Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2252-60. PubMed ID: 23868944
[TBL] [Abstract][Full Text] [Related]
3. Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: cardiac magnetic resonance substudy of the AIDA STEMI trial.
Eitel I; Wöhrle J; Suenkel H; Meissner J; Kerber S; Lauer B; Pauschinger M; Birkemeyer R; Axthelm C; Zimmermann R; Neuhaus P; Brosteanu O; de Waha S; Desch S; Gutberlet M; Schuler G; Thiele H
J Am Coll Cardiol; 2013 Apr; 61(13):1447-54. PubMed ID: 23466078
[TBL] [Abstract][Full Text] [Related]
4. Impact of system delay on infarct size, myocardial salvage index, and left ventricular function in patients with ST-segment elevation myocardial infarction.
Lønborg J; Schoos MM; Kelbæk H; Holmvang L; Steinmetz J; Vejlstrup N; Jørgensen E; Helqvist S; Saunamäki K; Bøtker HE; Kim WY; Terkelsen CJ; Clemmensen P; Engstrøm T
Am Heart J; 2012 Oct; 164(4):538-46. PubMed ID: 23067912
[TBL] [Abstract][Full Text] [Related]
5. Impact of primary coronary angioplasty delay on myocardial salvage, infarct size, and microvascular damage in patients with ST-segment elevation myocardial infarction: insight from cardiovascular magnetic resonance.
Francone M; Bucciarelli-Ducci C; Carbone I; Canali E; Scardala R; Calabrese FA; Sardella G; Mancone M; Catalano C; Fedele F; Passariello R; Bogaert J; Agati L
J Am Coll Cardiol; 2009 Dec; 54(23):2145-53. PubMed ID: 19942086
[TBL] [Abstract][Full Text] [Related]
6. Impact of acute hyperglycemia on myocardial infarct size, area at risk, and salvage in patients with STEMI and the association with exenatide treatment: results from a randomized study.
Lønborg J; Vejlstrup N; Kelbæk H; Nepper-Christensen L; Jørgensen E; Helqvist S; Holmvang L; Saunamäki K; Bøtker HE; Kim WY; Clemmensen P; Treiman M; Engstrøm T
Diabetes; 2014 Jul; 63(7):2474-85. PubMed ID: 24584550
[TBL] [Abstract][Full Text] [Related]
7. High-dose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial infarction.
Desmet W; Bogaert J; Dubois C; Sinnaeve P; Adriaenssens T; Pappas C; Ganame J; Dymarkowski S; Janssens S; Belmans A; Van de Werf F
Eur Heart J; 2011 Apr; 32(7):867-77. PubMed ID: 21196444
[TBL] [Abstract][Full Text] [Related]
8. Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia.
Lønborg J; Kelbæk H; Vejlstrup N; Bøtker HE; Kim WY; Holmvang L; Jørgensen E; Helqvist S; Saunamäki K; Terkelsen CJ; Schoos MM; Køber L; Clemmensen P; Treiman M; Engstrøm T
Circ Cardiovasc Interv; 2012 Apr; 5(2):288-95. PubMed ID: 22496084
[TBL] [Abstract][Full Text] [Related]
9. Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial.
Atar D; Petzelbauer P; Schwitter J; Huber K; Rensing B; Kasprzak JD; Butter C; Grip L; Hansen PR; Süselbeck T; Clemmensen PM; Marin-Galiano M; Geudelin B; Buser PT;
J Am Coll Cardiol; 2009 Feb; 53(8):720-9. PubMed ID: 19232907
[TBL] [Abstract][Full Text] [Related]
10. No benefit of additional treatment with exenatide in patients with an acute myocardial infarction.
Roos ST; Timmers L; Biesbroek PS; Nijveldt R; Kamp O; van Rossum AC; van Hout GP; Stella PR; Doevendans PA; Knaapen P; Velthuis BK; van Royen N; Voskuil M; Nap A; Appelman Y
Int J Cardiol; 2016 Oct; 220():809-14. PubMed ID: 27394978
[TBL] [Abstract][Full Text] [Related]
11. Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction N-ACC) Trial.
Thiele H; Hildebrand L; Schirdewahn C; Eitel I; Adams V; Fuernau G; Erbs S; Linke A; Diederich KW; Nowak M; Desch S; Gutberlet M; Schuler G
J Am Coll Cardiol; 2010 May; 55(20):2201-9. PubMed ID: 20466200
[TBL] [Abstract][Full Text] [Related]
12. Ischaemic postconditioning revisited: lack of effects on infarct size following primary percutaneous coronary intervention.
Freixa X; Bellera N; Ortiz-Pérez JT; Jiménez M; Paré C; Bosch X; De Caralt TM; Betriu A; Masotti M
Eur Heart J; 2012 Jan; 33(1):103-12. PubMed ID: 21846677
[TBL] [Abstract][Full Text] [Related]
13. Multiple biomarkers at admission are associated with angiographic, electrocardiographic, and imaging cardiovascular mechanistic markers of outcomes in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction.
Damman P; Kuijt WJ; Woudstra P; Haeck JD; Koch KT; Gu YL; van Straalen JP; Fischer J; Tijssen JG; Krucoff MW; de Winter RJ
Am Heart J; 2012 May; 163(5):783-9. PubMed ID: 22607855
[TBL] [Abstract][Full Text] [Related]
14. A high loading dose of clopidogrel reduces myocardial infarct size in patients undergoing primary percutaneous coronary intervention: a magnetic resonance imaging study.
Song YB; Hahn JY; Gwon HC; Chang SA; Lee SC; Choe YH; Choi SH; Choi JH; Lee SH; Oh JK
Am Heart J; 2012 Mar; 163(3):500-7. PubMed ID: 22424023
[TBL] [Abstract][Full Text] [Related]
15. Post-conditioning reduces infarct size and edema in patients with ST-segment elevation myocardial infarction.
Thuny F; Lairez O; Roubille F; Mewton N; Rioufol G; Sportouch C; Sanchez I; Bergerot C; Thibault H; Cung TT; Finet G; Argaud L; Revel D; Derumeaux G; Bonnefoy-Cudraz E; Elbaz M; Piot C; Ovize M; Croisille P
J Am Coll Cardiol; 2012 Jun; 59(24):2175-81. PubMed ID: 22676937
[TBL] [Abstract][Full Text] [Related]
16. Rationale and design of the 'F.I.R.E.' study. A multicenter, double-blind, randomized, placebo-controlled study to measure the effect of FX06 (a fibrin-derived peptide Bbeta(15-42)) on ischemia-reperfusion injury in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.
Atar D; Huber K; Rupprecht HJ; Kopecky SL; Schwitter J; Theek C; Brandl K; Henning R; Geudelin B
Cardiology; 2007; 108(2):117-23. PubMed ID: 17019083
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE).
Jang IK; Weissman NJ; Picard MH; Zile MR; Pettigrew V; Shen S; Tatsuno J; Hibberd MG; Tzivoni D; Wackers FJ;
Am Heart J; 2008 Jan; 155(1):113.e1-8. PubMed ID: 18082500
[TBL] [Abstract][Full Text] [Related]
18. Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: MITOCARE study results.
Atar D; Arheden H; Berdeaux A; Bonnet JL; Carlsson M; Clemmensen P; Cuvier V; Danchin N; Dubois-Randé JL; Engblom H; Erlinge D; Firat H; Halvorsen S; Hansen HS; Hauke W; Heiberg E; Koul S; Larsen AI; Le Corvoisier P; Nordrehaug JE; Paganelli F; Pruss RM; Rousseau H; Schaller S; Sonou G; Tuseth V; Veys J; Vicaut E; Jensen SE
Eur Heart J; 2015 Jan; 36(2):112-9. PubMed ID: 25179768
[TBL] [Abstract][Full Text] [Related]
19. Trial design and rationale of TY-51924 as a novel Na+/H+ exchanger inhibitor in patients with ST-elevation acute myocardial infarction undergoing percutaneous coronary intervention.
Ishihara M; Asakura M; Kimura K; Nakao K; Hamada C; Hirayama A
J Cardiol; 2014 Jan; 63(1):82-7. PubMed ID: 23860273
[TBL] [Abstract][Full Text] [Related]
20. Infarct size and left ventricular function in the PRoximal Embolic Protection in Acute myocardial infarction and Resolution of ST-segment Elevation (PREPARE) trial: ancillary cardiovascular magnetic resonance study.
Haeck JD; Kuijt WJ; Koch KT; Bilodeau L; Henriques JP; Rohling WJ; Baan J; Vis MM; Nijveldt R; van Geloven N; Groenink M; Piek JJ; Tijssen JG; Krucoff MW; De Winter RJ
Heart; 2010 Feb; 96(3):190-5. PubMed ID: 19858136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
